Uncontrolled bleeding and infection can lead to a significant increase in mortality. Hydrogel sealant has attracted wide attention because of their ability to control bleeding. However, because water interface is a formidable barrier to a strong bonding surface, the challenge remains in finding a product that offers a strong network adhesion combined with anti-infective properties. Inspired by the mechanism of strong adhesive on the biofilm and mussels, we report a novel dual hydrogel adhesive bionic (DBAH) based on chitosan grafted with methacrylate (CS-MA), dopamine (DA), and N-hydroxymethyl acrylamide (NMA) through smooth a process radical polymerization.
CS-MA and DA simultaneously included in the adhesive polymer to mimic the key two-component adhesive: inter polysaccharide adhesin (PIA) on staphylococcal biofilms and 3,4-dihydroxy-L-phenylalanine (DOPA) of the protein shells foot, respectively. DBAH presented strong adhesion at 34 kPa even after three cycles of full immersion in water and can survive up to 168 mm Hg blood pressure, which is significantly higher than the 60-160 mm Hg measured in most clinical settings. Most importantly, these hydrogels presented remarkable hemostatic ability under wet and dynamic in vivo movement while displaying excellent antibacterial properties and biocompatibility. Therefore, DBAH a promising class of biomaterials for high efficiency hemostasis and wound healing.
The eluate denture adhesive is brought into contact with human gingival cells and compared to cells not treated (w / o any elution dental adhesives). cell toxicity was assessed by measuring cell viability (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) (MTT) test), the morphology of the cells (immunofluorescence assay), induction of apoptosis / necrosis and the production of oxygen species reactive (ROS) (flow cytometry tests). In addition, the pH of each sample was determined. Data were analyzed using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test.
Biofilm-inspired adhesive and antibacterial hydrogel with tough tissue integration performance for sealing hemostasis and wound healing
Chronic venous ulcers: a review of treatment with fibrin sealant and prognostic progress using proteomics strategy
Venous ulcers are a major cause of ulcers of lower-limb chronic. Difficulty healing encourage research and development of new products to achieve better therapeutic results. Fibrin sealant is one of the alternative routes. In addition to being validated scaffolding and drug delivery systems, it has excellent healing properties. This review covers the last 25 years of literature and shows that fibrin sealant used in a variety of clinical situations to promote the healing of various types of ulcers, particularly chronic. These are mostly veins in origin and usually do not respond to conventional treatment.
Commercially, only homologous fibrin sealant derived from human blood are available, which is very efficient but very expensive. The heterologous fibrin sealant is an experimental product non-commercial cost and easily manufactured because of the raw material. Phase I / II clinical trial has been completed and indicates that the product is safe and efficacious promisingly for the treatment of chronic venous ulcers. In addition, clinical proteomics strategy to assess the prognosis of the disease has been increasingly used.
Description: Interleukin-3 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 154 amino acids fragment (20-152) and having a total molecular mass of 17.3kDa and fused with a 20 aa N-terminal His tag. ;The IL3 His is purified by proprietary chromatographic techniques.
By analyzing a sample of fluid from the wound through proteomics strategy, it is possible to predict before treatment ulcers will develop positively and which will be difficult to cure. This prognosis is only possible to evaluate the expression of proteins isolated in exudate and analysis using free label strategy for the shotgun. multicentre clinical trials will be required to evaluate the efficacy of fibrin sealant to treat chronic ulcers, as well as to validate the proteomics strategies for assessing prognosis.
Sarah
)
)
)
 Antibody)
